BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Probably not in the way some might think.

Could Coronavirus Variants Boost Pfizer's Vaccine Sales By 50%?

AstraZeneca

A recent study revealed that one dose of either Pfizer Inc (NYSE: PFE)/BioNtech SE (NASDAQ: BNTX) or Oxford-AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine is more than 80% effective in reducing infections and severe illness among those aged over 80, Reuters reports. Public Health England (PHE) found that the Pfizer jab offered between 57% and 61% protection against catching the disease after the first dose.

AstraZeneca, Pfizer/BioNtech Single Shot COVID-19 Jab 80% Effective At Preventing Hospitalizations In Elderly

Flowserve

Flowserve Corp, an American supplier of industrial machinery, said on Monday it was providing pumps, valves and seals to Pfizer Inc to support the production of its COVID-19 vaccine.

Flowserve supplying pumps, valves for Pfizer vaccine production

A single dose of the COVID-19 vaccine made by Pfizer and BioNTech reduces infections and lowers the risk of transmission, according to a new study.

Pfizer vaccine can reduce transmission after 1 dose, new study finds

Your free daily email from Fuller Treacy Money Comments of the Day 26 February 2021   Video commentary for February 25th 2021   Eoin Treacy's view A link to today's video commentary is posted in the Subscriber's Area.  Some of the topics discussed include: Treasury yields spike higher, stcocks and bonds pause, oil eases, gold weak, bitcoin steady yield curve steepening.

"Real world" test of Pfizer COVID-19 vaccine in Israel determines effectiveness in preventing illness

This change could make handling the vaccine easier for small clinics with few resources.

Pfizer's Covid Vaccine Doesn't Need Ultra-Cold Storage, FDA Says

Moderna

Moderna, Inc. (NASDAQ:MRNA) said it expects to make US$18.4bn (£13bn) in revenue this year as governments worldwide have booked millions of doses of its COVID-19 vaccine. In 2020, total revenue rocketed 93% to US$803mln, mostly due to grants by the US government to speed up the development of the jab.

Coronavirus: Moderna forecasts US$18.4bn sales this year, Pfizer/BioNTech vaccine proved highly effective by study on 1.2mln people

Pfizer Inc. and BioNTech SE said Thursday they have initiated the evaluation of a third dose of their COVID-19 vaccine, to study the effect of a booster on new SARS-CoV-2 variants. The study will draw on participants of its Phase 1 study in the U.S., who will be offered the opportunity to receive a booster of the current vaccine six to 12 months after receiving their initial two doses.

Pfizer, BioNTech to test a COVID-19 vaccine booster against new SARS-CoV-2 variants

A real-world study of the coronavirus vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) showed the drug to be 94 percent effective at preventing COVID-19. What Happened: The large-scale study conducted in Israel found the two-dose vaccine reduced symptomatic cases by 94 percent one week after the second dose and also reduced the severity of the disease by 92 percent, Nikkei Asia reported on Thursday.

Pfizer-BioNTech Vaccine 94% Effective In Real World: Study

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the oppor

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

The FDA has signaled an eagerness in recent days for progress on vaccines that can offer protection from the emerging variants.

Pfizer Will Test Third Dose of Vaccine to Protect Against Variants

Pfizer and BioNTech announced this morning that they plan to study the effects of a third COVID-19 vaccine dose in participants from its original clinical trial. The companies will offer booster shots to up to 144 participants six to 12 months after they received their second dose of the vaccine. The Phase 1 trial kicked off in May 2020, so some people who participated are already eligible for their third doses.

Pfizer is testing out a 3rd booster shot to bolster its COVID-19 vaccine against new variants

Pfizer sees $15 billion revenue from the Pfizer/BioNTech COVID vaccine in 2021 and it could completely change Pfizer's revenue and earnings trajectory. Think about what this will do for BioNTech. The above revenues are for the “pandemic phase.” Pfizer/BioNTech may be considering a 3-4x price increase for their COVID-19 vaccine(s) after this phase. Read this sentence again.

COVID-19 Continues, But Good Times For mRNA Vaccine Developers Pfizer/BioNTech And Moderna

The FDA has accepted  Pfizer Inc's (NYSE: PFE) marketing application seeking approval for TicoVac under priority review status. TicoVac is the tick-borne encephalitis (TBE) vaccine for active immunization in individuals aged one and older.

Pfizer's Tick-Borne Encephalitis Vaccine Gets Priority Review Tag In US

Johnson & Johnson

Pfizer Inc. (NYSE: PFE), Moderna Inc. (Nasdaq: MRNA) and Johnson & Johnson (NYSE: JNJ) said they are committed to making a total of 240 million doses of COVID-19 vaccines available in the U.S. by the end of March. What Happened: The drug makers told a House subcommittee on Tuesday they are working on ramping up production of their vaccines to meet demand.

Pfizer, Moderna, J&J Pledge To Make 240M COVID-19 Vaccine Doses Available In US By March-End

Pfizer and Moderna said Tuesday they're making improvements that will allow them to deliver more vaccines in the coming months.

Pfizer And Moderna To Dramatically Increase Covid-19 Vaccine Production This Spring

On BioNTech's (BNTX) fourth-quarter earnings call, investors are likely to focus on sales number for its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.

What's in the Cards for BioNTech (BNTX) This Earnings Season?

Last week, there were two positive developments relating to Pfizer and its German partner BioNTech's Covid-19 vaccine, and one possible negative development. Firstly, Pfizer says based on internal testing that its vaccine can tolerate warmer temperatures than initially specified, possibly making.

Pfizer Vaccine Updates: Possibly Easier Storage, Efficacy Against South African Strain

Eli Lilly

Regeneron Pharmaceuticals

The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.

FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs

2 Reasons Pfizer's COVID Vaccine Prospects Just Got Even Better

“We should be very encouraged by these initial findings,” said the head of Public Health England.

Pfizer Vaccine Highly Effective After Just One Dose, U.K. Early Data Suggest

An initial dose of the vaccine made by Pfizer and BioNTech cuts the risk of coronavirus infection, Public Health England announced on Monday as U.K. Prime Minister Boris Johnson confirmed plans to relax lockdown rules.

Pfizer vaccine reduces coronavirus-infection risk, Public Health England says

The Israel health ministry said that Pfizer Inc (NYSE: PFE) and BioNtech SE's (NASDAQ: BNTX) COVID-19 vaccine had proved 95.8% effective in preventing coronavirus infection among those vaccinated two weeks after receiving their second shot, compared to unvaccinated people, according to data compiled up to February 13. The shot appeared to stop the vast majority of vaccine recipients in Israel from COVID-19 infection, providing the first real-world indication that the immunization will curb transmission of the coronavirus, the health ministry reported.

Pfizer/BioNtech's COVID-19 Shot Staved Off Illness, Death For Over 95% Of Israeli patients

That's good news for the rest of the world.

Pfizer's Covid Vaccine Over 95% Effective In Israel, New Study Reportedly Shows

The new findings promise simpler transport, storage, and administration for BNT162b2.

News for BioNTech SE Stock (BNTX)